抗小鼠VEGF单克隆抗体(克隆号B20-4.1.1.1) ，体内实验级重组，小鼠IgG2a kappa | Syd Labs PA007513.m2a
体内实验级重组抗小鼠VEGF单克隆抗体，小鼠IgG2a kappa(克隆号：B20-4.1.1.1，货号：PA007513.m2a)是用哺乳动物细胞生产的重组抗体，纯度>95%，适用于体内和体外研究，比如体内 VEGF-A 中和、体内肿瘤血管生成抑制。Syd Labs PA007513.m2a不变区为小鼠Mouse IgG2a Kappa (mIgG2a或m2a)，可与重组小鼠IgG2a同型对照抗体配套使用。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。
- 产品参数
- 文献
- More Offers
| 货号 | PA007513.m2a |
|---|---|
| 产品名称 | 抗小鼠VEGF单克隆抗体(克隆号B20-4.1.1.1) ，体内实验级重组，小鼠IgG2a kappa | Syd Labs PA007513.m2a |
| 英文名 | In Vivo Grade Recombinant Anti-mouse VEGF Monoclonal Antibody (Clone: B20-4.1.1.1), Mouse IgG2a Kappa |
| 供货商名称 | Syd Labs, Inc. |
| 品牌名 | Syd Labs |
| 别称 | 血管内皮生长因子、VEGF |
| 概述 | Syd Labs提供重组小鼠IgG2a同型对照抗体。样品制备条件和最佳样品稀释应由研究人员通过实验确定。 |
| 克隆号 | B20-4.1.1.1 |
| 同种型 | 小鼠 IgG2a kappa |
| 特异性 | 体内实验级重组小鼠单克隆抗体（克隆：B20-4.1.1.1）特异性结合小鼠VEGF |
| 应用 | ELISA、中和、功能测定，如生物分析PK和ADA测定，以及用于研究小鼠VEGF蛋白影响的生物途径的测定。 |
| 抗体形式 | 0.2 μM过滤溶液，1x PBS |
| 内毒素 | 根据 LAL 方法，≤1 EU每1mg 蛋白质 |
| 纯度 | >95%（在还原条件下通过SDS-PAGE测定） |
| 运输 | 体内实验级重组抗小鼠VEGF单克隆抗体，小鼠IgG2a kappa(克隆号B20-4.1.1.1)用冰袋运输。收到后，请立即将其存放在下面建议的温度下。 |
| 稳定性与存储 | 使用手动除霜冰箱并避免重复冻融循环。 自收到之日起 1 个月，保存在2 至 8°C。 自收到之日起12个月，保存在-20 至 -70°C。 |
| 注意事项 | PA007513.m2a Syd Labs：体内实验级重组抗小鼠VEGF小鼠IgG2a kappa单克隆抗体是用哺乳动物细胞生产的重组抗体，可与重组小鼠IgG2a同型对照抗体配套使用。样品制备条件和最佳样品稀释应由研究人员通过实验确定。 |
| 产品咨询 | Syd Labs在国内只通过代理商销售其产品，不做直销。终端用户咨询价格请联系Syd Labs中国代理商。 关于Syd Labs产品如果有任何技术或其它问题，欢迎随时联系Syd Labs国内市场推广合作伙伴：武汉多找找科技有限公司，企业微信：duozhaozhao2024 联系电话：18162581039（龙经理） |
描述
PA007513.m2a：Syd Labs体内实验级重组抗小鼠VEGF单克隆抗体(克隆号B20-4.1.1.1)，小鼠IgG2a kappa(In Vivo Grade Recombinant Anti-mouse VEGF Monoclonal Antibody (Clone: B20-4.1.1.1), Mouse IgG2a Kappa)
抗小鼠VEGF抗体（B20-4.1.1）部分参考文献:
1、Endothelial F3-mediated autolysosome and lipid metabolism promote resistance to anti-VEGFA therapy in metastatic colorectal cancer
Nan Huang et al. Autophagy 2025 Dec;21(12):3004-3023. doi: 10.1080/15548627.2025.2551720. Epub 2025 Sep 8. PMID: 40922383
“Patients with metastatic colorectal cancer (mCRC) to the liver exhibit poor survival rates. Chemotherapy combined with anti-vascular therapy has emerged as the standard treatment, but resistance to anti-VEGFA therapy inevitably develops. The metabolic reprogramming of tumor vascular endothelial cells (TECs) plays a crucial, yet still poorly understood, role in the development of therapeutic resistance. We identified lipid-rich and fatty acid oxidation (FAO)-activated proliferating TECs in fatty colorectal cancer liver metastasis (CRLM) that mediate resistance to anti-VEGFA treatment. The TEC-specific F3 protein inhibited the macroautophagy/autophagy-lysosome pathway through the MAPK/JNK-MAPK/ERK-TP53/p53 signaling axis, thereby prevented CPT1A protein degradation and enhanced FAO. F3 was also involved in promoting lipid uptake and lipophagy. This process promoted cellular FAO under conditions of fatty acids and anti-VEGFA stimulation. Targeting FAO proved effective in overcoming resistance to anti-VEGFA treatment. Our findings elucidated the role of lipid metabolism in therapy-resistant TECs in fatty CRLM and provided a theoretical foundation for further research on anti-VEGFA therapy resistance. Moreover, we underscored the potential of combining FAO inhibitors to enhance the efficacy of anti-angiogenic therapy.”
Tags: anti-mouse VEGF antibody; anti-mouse VEGF antibody for cancer research
2、Radiosensitizing oxygenation changes in murine tumors treated with VEGF-ablation therapy are measurable using oxygen enhanced-MRI (OE-MRI)
Jennifer Hazel Elizabeth Baker, Andrew I Minchinton et al. Radiother Oncol. 2023. PMID: 37414252
“Murine squamous cell carcinoma (SCCVII) tumor-bearing mice were treated with 5 mg/kg anti-VEGF murine antibody B20 (B20-4.1.1, Genentech) 2-7 days prior to radiation treatment, tissue collection or MR imaging using a 7 T scanner. dOE-MRI scans were acquired for a total of three repeated cycles of air (2 min) and 100% oxygen (2 min) with responding voxels indicating tissue oxygenation. DCE-MRI scans were acquired using a high molecular weight (MW) contrast agent (Gd-DOTA based hyperbranched polygylcerol; HPG-GdF, 500 kDa) to obtain fractional plasma volume (fPV) and apparent permeability-surface area product (aPS) parameters derived from the MR concentration-time curves. Changes to the tumor microenvironment were evaluated histologically, with cryosections stained and imaged for hypoxia, DNA damage, vasculature and perfusion. Radiosensitizing effects of B20-mediated increases in oxygenation were evaluated by clonogenic survival assays and by staining for DNA damage marker γH2AX.”
Tags: anti-mouse VEGF antibody; anti-mouse VEGF antibody for cancer research
3、Modulation of vascular response after injury in the rat Achilles tendon alters healing capacity
Corinne N Riggin, Benjamin R Freedman, Meghna S Murthy et al. J Orthop Res. 2021. PMID: 32936495
“Fischer rats received a bilateral Achilles incisional injury followed by local injections of vascular endothelial growth factor (VEGF), anti-VEGF antibody (B20.4-1-1), or saline either early or late during the healing process. Vascular modulation and healing were evaluated using multiple in vivo ultrasound imaging modalities, in vivo functional assessment, and ex vivo measures of tendon compositional and mechanical properties. The late delivery of anti-VEGF antibody, B20, caused a temporary reduction in healing capacity during a time point where vascularity was also decreased, and then an improvement during a later time point where vascularity was increased relative to control. However, VEGF delivery had a minimal impact on healing and vascular changes in both early and late delivery times. This study was the first to evaluate vascular changes using both in vivo imaging methods and ex vivo histological methods, as well as functional and mechanical outcomes associated with these vascular changes. Clinical significance: this study demonstrates that the alteration of vascular response through the delivery of angiogenic growth factors has the ability to alter tendon healing properties.”
Tags: anti-mouse VEGF B20-4.1.1 mAb in animal model; anti-mouse VEGF B20-4.1.1 in cancer research
4、TNFα secreted by glioma associated macrophages promotes endothelial activation and resistance against anti-angiogenic therapy
Qingxia Wei, Ivana Zubiaurre Martinez et al. Acta Neuropathol Commun. 2021. PMID: 33853689
“We further demonstrated in mouse model that treatment with B20.4.1.1, the mouse analog of Bevacizumab, increased macrophage recruitment to the tumor area and correlated with upregulated TNFalpha expression in GAMs and increased EC activation, which may be res …”
Tags: bioactivity of anti-mouse VEGF B20-4.1; anti-mouse VEGF B20-4.1 of low endotoxin
了解更多抗小鼠VEGF单克隆抗体（clone：B20-4.1.1）参考文献，欢迎联系我们（咨询微信：duozhaozhao2024）。
Syd Labs 抗小鼠VEGF单克隆抗体(克隆号B20-4.1.1.1)，小鼠IgG2a kappa（货号：PA007513.m2a）推荐同型对照抗体:
Syd Labs提供以下抗小鼠VEGFA单克隆抗体:
In vivo grade recombinant anti-mouse VEGFA monoclonal antibodies (Clone B20-4.1.1.1))
In vivo grade recombinant anti-mouse VEGF-A monoclonal antibodies (Clone G6-31)
In vivo grade recombinant anti-mouse VEGF monoclonal antibodies (Clone G6-23)
Syd Labs提供以下抗小鼠PD-1/VEGFA双特异性抗体:
In vivo grade recombinant anti-mouse PD-1 / VEGF-A bispecific antibodies (Clone RMP1-14.1 / B20-4.1.1.1)
In vivo grade recombinant anti-mouse PD1 / VEGFA bispecific antibodies (Clone 29F.1A12.1 / B20-4.1.1.1)
In vivo grade recombinant anti-mouse PD-1 / VEGF bispecific antibodies (Clone RMP1-14.1 / G6-23)
In vivo grade recombinant anti-mouse PD1 / VEGF bispecific antibodies (Clone 29F.1A12.1 / G6-23)
In vivo grade recombinant anti-mouse PD 1 / VEGF bispecific antibodies (Clone RMP1-14.1 / G6-31)
In vivo grade recombinant anti-mouse PD-1 / VEGF A bispecific antibodies (Clone 29F.1A12.1 / G6-31)
Syd Labs提供以下抗小鼠PD-L1/VEGFA双特异性抗体:
In vivo grade recombinant anti-mouse PD-L1 / VEGF-A bispecific antibodies (Clone 10F.9G2.1 / B20-4.1.1.1)
In vivo grade recombinant anti-mouse PD-L1 / VEGF bispecific antibodies (Clone 10F.9G2.1 / G6-23)
In vivo grade recombinant anti-mouse PDL1 / VEGF bispecific antibodies (Clone 10F.9G2.1 / G6-31)
Syd Labs提供以下重组抗小鼠VEGF单克隆抗体（流式细胞术用）:
Recombinant Anti-mouse VEGF Monoclonal Antibody (Clone: B20-4.1.1.1) for Flow Cytometry
Recombinant Anti-mouse VEGF Monoclonal Antibody (Clone: G6-23) for Flow Cytometry
Recombinant Anti-mouse VEGF Monoclonal Antibody (Clone: G6-31) for Flow Cytometry
Syd Labs提供以下重组抗VEGF抗体生物类似药蛋白:
Bevacizumab Biosimilar, research grade, anti-human VEGF monoclonal antibody
Bevacizumab Biosimilar, L234A L235A P329G (LALAPG) Fc silent mutant
Ramucirumab Biosimilar, research grade, anti-human VEGF / VEGFR2 / VEGFR-2 monoclonal antibody
Ranibizumab Biosimilar, research grade, anti-human VEGF monoclonal antibody
Brolucizumab Biosimilar, research grade, VEGF-A Monoclonal Antibody
Faricimab Biosimilar, research grade, Human ANGPT2/VEGFA Monoclonal Antibody
请记住我们的产品信息: 体内实验级重组抗小鼠VEGF单克隆抗体(克隆号B20-4.1.1.1)，小鼠IgG2a kappa: PA007513.m2a Syd Labs In Vivo Grade Recombinant Anti-mouse VEGF Monoclonal Antibody (Clone: B20-4.1.1.1), Mouse IgG2a Kappa。